Status:
COMPLETED
Pharmacological Intervention in Insulin Resistance Targeting Autonomic Nerve Activity
Lead Sponsor:
AstraZeneca
Conditions:
Insulin Resistance
Eligibility:
All Genders
18-60 years
Phase:
EARLY_PHASE1
Brief Summary
The present study on pharmacological intervention in autonomic nervous dysregulation(parasympathetic dysfunction,) regarding insulin resistance, is a concept testing in humans tohelp identify potentia...
Eligibility Criteria
Inclusion
- Signed written informed consent
- BMI of lean and abdominally obese men and women
- weight stable
Exclusion
- Ongoing clinically significant diseases
- History of repeated syncope
- resting pulse\<50 or systolic blood pressure \<100
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2008
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00689208
Start Date
May 1 2007
End Date
November 1 2008
Last Update
March 13 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Gothenburg, Sweden